VCNX
Income statement / Annual
Last year (2023), Vaccinex, Inc.'s total revenue was $570,000.00,
an increase of 470.00% from the previous year.
In 2023, Vaccinex, Inc.'s net income was -$20.25 M.
See Vaccinex, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$570,000.00
|
$100,000.00
|
$900,000.00
|
$50,000.00
|
$523,000.00
|
$724,000.00
|
$90,000.00
|
$316,000.00
|
| Cost of Revenue |
$119,000.00 |
$207,000.00 |
$169,000.00 |
$2,000.00 |
$199,000.00 |
$1.03 M |
$160,000.00 |
$115,000.00 |
| Gross Profit |
$451,000.00 |
-$107,000.00 |
$731,000.00 |
$48,000.00 |
$324,000.00 |
-$309,000.00 |
-$70,000.00 |
$201,000.00 |
| Gross Profit Ratio |
0.79 |
-1.07 |
0.81 |
0.96 |
0.62 |
-0.43 |
-0.78 |
0.64 |
| Research and Development
Expenses |
$16.45 M
|
$13.98 M
|
$17.16 M
|
$21.55 M
|
$25.67 M
|
$22.35 M
|
$16.55 M
|
$16.03 M
|
| General & Administrative
Expenses |
$6.88 M
|
$6.20 M
|
$6.23 M
|
$7.41 M
|
$6.67 M
|
$4.62 M
|
$4.48 M
|
$4.43 M
|
| Selling & Marketing
Expenses |
$181,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.88 M
|
$6.20 M
|
$6.23 M
|
$7.41 M
|
$6.67 M
|
$4.62 M
|
$4.48 M
|
$4.43 M
|
| Other Expenses |
$912,000.00 |
-$175,000.00 |
$43,000.00 |
-$575,000.00 |
$152,000.00 |
$165,000.00 |
-$40,000.00 |
-$4,000.00 |
| Operating Expenses |
$23.34 M |
$20.01 M |
$23.39 M |
$28.38 M |
$32.34 M |
$26.97 M |
$21.03 M |
$20.46 M |
| Cost And Expenses |
$23.46 M |
$20.01 M |
$23.39 M |
$28.38 M |
$32.54 M |
$28.01 M |
$21.19 M |
$20.58 M |
| Interest Income |
$0.00 |
$2,000.00 |
$809,000.00 |
$489,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1,000.00 |
$2,000.00 |
$809,000.00 |
$489,000.00 |
$0.00 |
$392,000.00 |
$1.36 M |
$2.99 M |
| Depreciation &
Amortization |
$119,000.00
|
$207,000.00
|
$169,000.00
|
$307,000.00
|
$249,000.00
|
$223,000.00
|
$206,000.00
|
$178,000.00
|
| EBITDA |
-$22.77 M
|
-$19.61 M
|
-$22.28 M
|
-$28.06 M
|
-$31.61 M
|
-$26.89 M
|
-$20.94 M
|
-$20.09 M
|
| EBITDA Ratio |
-39.94 |
-196.06 |
-24.75 |
-561.1 |
-60.45 |
-37.15 |
-232.64 |
-63.56 |
| Operating Income Ratio
|
-40.15
|
-199.06
|
-24.99
|
-566.62
|
-61.21
|
-37.68
|
-234.49
|
-64.11
|
| Total Other
Income/Expenses Net |
$2.63 M
|
$91,000.00
|
$110,000.00
|
-$520,000.00
|
$152,000.00
|
-$1.85 M
|
$3.70 M
|
$9.31 M
|
| Income Before Tax |
-$20.25 M |
-$19.82 M |
-$22.38 M |
-$28.85 M |
-$31.86 M |
-$29.52 M |
-$18.76 M |
-$13.94 M |
| Income Before Tax Ratio
|
-35.53
|
-198.15
|
-24.87
|
-577.02
|
-60.92
|
-40.77
|
-208.43
|
-44.12
|
| Income Tax Expense |
-$48,895.00 |
-$93,000.00 |
$852,000.00 |
$458,000.00 |
$152,000.00 |
-$1.85 M |
$1.28 M |
$2.99 M |
| Net Income |
-$20.25 M |
-$19.72 M |
-$23.23 M |
-$29.31 M |
-$32.02 M |
-$29.52 M |
-$18.72 M |
-$13.94 M |
| Net Income Ratio |
-35.53 |
-197.22 |
-25.81 |
-586.18 |
-61.21 |
-40.77 |
-208.02 |
-44.12 |
| EPS |
-43.68 |
-97.59 |
-170.04 |
-327.62 |
-521.95 |
-1186.7 |
-689.86 |
-526.85 |
| EPS Diluted |
-43.68 |
-97.59 |
-169.11 |
-327.62 |
-521.95 |
-1186.7 |
-689.86 |
-526.85 |
| Weighted Average Shares
Out |
$463,653.00
|
$202,082.00
|
$136,630.00
|
$89,461.00
|
$61,337.00
|
$24,874.00
|
$27,139.00
|
$26,465.00
|
| Weighted Average Shares
Out Diluted |
$463,653.00
|
$202,082.00
|
$137,377.00
|
$89,461.00
|
$61,337.00
|
$24,874.00
|
$27,139.00
|
$26,465.00
|
| Link |
|
|
|
|
|
|
|
|
